Skip to main content Accessibility help
×
Home

Treatment with antipsychotics and the risk of diabetes in clinical practice

  • Lars Vedel Kessing (a1), Anders Frøkjær Thomsen (a1), Ulla Brasch Mogensen (a2) and Per Kragh Andersen (a2)

Abstract

Background

Treatment with antipsychotics seems to increase the risk of developing diabetes but the association is poorly characterised in clinical practice.

Aims

To investigate and characterise the incidence of diabetes for people treated with antipsychotic medication in clinical practice.

Method

The study used the linkage of registers of all prescribed antipsychotics, antidiabetics and diagnoses of diabetes in Denmark during a period from 1996 to 2005 and identified all people treated with antipsychotics in Denmark and a random sample of about 30% of the total Danish population.

Results

In total, 345 937 patients who purchased antipsychotics and 1 426 488 unexposed individuals were included in the study. Among the total population, 50 379 individuals subsequently developed incident diabetes. Compared with unexposed individuals, treatment with first- (rate ratio, RR = 1.53, 95% CI 1.49–1.56) as well as second-generation (RR = 1.32, 95% CI 1.22–1.42) antipsychotics was associated with increased risk of subsequent incident diabetes. The rate of incident diabetes varied substantially between individual second-generation antipsychotic drugs (olanzapine, risperidone clozapine compared with unexposed individuals: low to moderate rate ratio between 1.17 and 1.57; ziprasidone and sertindol: two or more times increased rate ratio; amisulpride, quetiapine and aripiprazole: no significantly increased rate ratio). For both first- and second-generation antipsychotics, the incidence of diabetes increased with the number of prescriptions. Additionally, the incidence of diabetes increased with the number of combined antipsychotic drugs.

Conclusions

In clinical practice, treatment with first- and second-generation antipsychotics is associated with an increased risk of developing incident diabetes with large differences between individual drugs. The risk increases with the duration of treatment and with polypharmacy of antipsychotic drugs.

  • View HTML
    • Send article to Kindle

      To send this article to your Kindle, first ensure no-reply@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about sending to your Kindle. Find out more about sending to your Kindle.

      Note you can select to send to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be sent to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

      Find out more about the Kindle Personal Document Service.

      Treatment with antipsychotics and the risk of diabetes in clinical practice
      Available formats
      ×

      Send article to Dropbox

      To send this article to your Dropbox account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your <service> account. Find out more about sending content to Dropbox.

      Treatment with antipsychotics and the risk of diabetes in clinical practice
      Available formats
      ×

      Send article to Google Drive

      To send this article to your Google Drive account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your <service> account. Find out more about sending content to Google Drive.

      Treatment with antipsychotics and the risk of diabetes in clinical practice
      Available formats
      ×

Copyright

Corresponding author

Lars Vedel Kessing, Department of Psychiatry, University Hospital of Copenhagen, Rigshospitalet, Blegdamsvej 9, DK 2100 Copenhagen Ø, Denmark. Email: lars.vedel.kessing@regionh.dk

Footnotes

Hide All

Declaration of interest

L.V.K. has been a consultant for Bristol-Myers Squibb, Eli Lilly, Lundbeck, AstraZenica, Pfizer, Wyeth, Servier and Janssen-Cilag.

Footnotes

References

Hide All
1 Domino, ME, Swartz, MS. Who are the new users of antipsychotic medications? Psychiatr Serv 2008; 59: 507–14.
2 Dabelea, D. The accelerating epidemic of childhood diabetes. Lancet 2009; 373: 19992000.
3 Mukherjee, S, Decina, P, Bocola, V, Saraceni, F, Scapicchio, PL. Diabetes mellitus in schizophrenic patients. Compr Psychiatry 1996; 37: 6873.
4 Dixon, L, Weiden, P, Delahanty, J, Goldberg, R, Postrado, L, Lucksted, A, et al. Prevalence and correlates of diabetes in national schizophrenia samples. Schizophr Bull 2000; 26: 903–12.
5 Regenold, WT, Thapar, RK, Marano, C, Gavirneni, S, Kondapavuluru, PV. Increased prevalence of type 2 diabetes mellitus among psychiatric inpatients with bipolar I affective and schizoaffective disorders independent of psychotropic drug use. J Affect Disord 2002; 70: 1926.
6 Buse, JB, Cavazzoni, P, Hornbuckle, K, Hutchins, D, Breier, A, Jovanovic, L. A retrospective cohort study of diabetes mellitus and antipsychotic treatment in the United States. J Clin Epidemiol 2003; 56: 164–70.
7 Ramaswamy, K, Masand, PS, Nasrallah, HA. Do certain atypical antipsychotics increase the risk of diabetes? A critical review of 17 pharmacoepidemiologic studies. Ann Clin Psychiatry 2006; 18: 183–94.
8 Smith, M, Hopkins, D, Peveler, RC, Holt, RIG, Woodward, M, Ismail, K. First- v. second-generation antipsychotics and risk for diabetes in schizophrenia: systematic review and meta-analysis. Br J Psychiatry 2008; 192: 406–11.
9 Saddichha, S, Manjunatha, N, Ameen, S, Akhtar, S. Diabetes and schizophrenia – effect of disease or drug? Results from a randomized, double-blind, controlled prospective study in first-episode schizophrenia. Acta Psychiatr Scand 2008; 117: 342–7.
10 Lieberman, JA, Stroup, TS, McEvoy, JP, Swartz, MS, Rosenheck, RA, Perkins, DO, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 2005; 353: 1209–23.
11 Malig, C. The Civil Registration System in Denmark. Technical Paper No 66. International Institute for Vital Registration and Statistics, 1996.
12 Danish National Board of Health, Lægemiddelstyrelsen. Medicinal Product Statistics. Lægemiddelstyrelsen, 2002 (http://www.laegemiddelstyrelsen.dk).
13 Juel, K, Helweg-Larsen, K. The Danish registers of causes of death. Dan Med Bull 1999; 46: 354–7.
14 Andersen, TF, Madsen, M, Jorgensen, J, Mellemkjaer, L, Olsen, JH. The Danish National Hospital Register. A valuable source of data for modern health sciences. Dan Med Bull 1999; 46: 263–8.
15 Munk-Jorgensen, P, Mortensen, PB. The Danish Psychiatric Central Register. Dan Med Bull 1997; 44: 82–4.
16 WHO Collaborating Centre for Drug Statistics Methodology. ATC Index with DDDs. WHO Collaborating Centre for Drug Statistics Methodology, 2003.
17 World Health Organization. Glossary of Mental Disorders and Guide to their Classification for Use in Conjunction with the International Classification of Diseases, 8th Revision. WHO, 1974.
18 World Health Organization. International Statistical Classification of Diseases and Health Related Problems, 10th revision [Danish version]. Munksgaard, 1993.
19 Gianfrancesco, FD, Grogg, AL, Mahmoud, RA, Wang, RH, Nasrallah, HA. Differential effects of risperidone, olanzapine, clozapine, and conventional antipsychotics on type 2 diabetes: findings from a large health plan database. J Clin Psychiatry 2002; 63: 920–30.
20 Gianfrancesco, F, Grogg, A, Mahmoud, R, Wang, RH, Meletiche, D. Differential effects of antipsychotic agents on the risk of development of type 2 diabetes mellitus in patients with mood disorders. Clin Ther 2003; 25: 1150–71.
21 American Diabetes Association, American Psychiatric Association, American Association of Clinical Endocrinologists, North American Association for the Study of Obesity. Consensus development conference on antipsychotic drugs and obesity and diabetes. J Clin Psychiatry 2004; 65: 267–72.
22 Newcomer, JW, Nasrallah, HA, Loebel, AD. The Atypical Antipsychotic Therapy and Metabolic Issues National Survey: practice patterns and knowledge of psychiatrists. J Clin Psychopharmacol 2004; 24: S16.
23 Yood, MU, DeLorenze, G, Quesenberry, CP Jr, Oliveria, SA, Tsai, AL, Willey, VJ, et al. The incidence of diabetes in atypical antipsychotic users differs according to agent–results from a multisite epidemiologic study. Pharmacoepidemiol Drug Saf 2009; 18: 791–9.
24 Kristensen, JK. Identification of the Type 2 Diabetes Population in a Danish County and Evaluation of the Performed Care in a Five-Year Period. Aarhus Universitet, 2000.
25 Drivsholm, TB, Frederiksen, K, de Fine, ON, Odegaard, B, Kristensen, JK. The prevalence of diabetes in Denmark. Development of a method for a registry-based assessment [in Danish]. Ugeskr Laeger 2003; 165: 2887–91.
26 Leslie, DL, Rosenheck, RA. Incidence of newly diagnosed diabetes attributable to atypical antipsychotic medications. Am J Psychiatry 2004; 161: 1709–11.
27 Jin, H, Meyer, JM, Jeste, DV. Phenomenology of and risk factors for new-onset diabetes mellitus and diabetic ketoacidosis associated with atypical antipsychotics: an analysis of 45 published cases. Ann Clin Psychiatry 2002; 14: 5964.
28 Centers for Disease Control and Prevention. National Diabetes Surveillance System. Centers for Disease Control and Prevention, 2009 (http://apps.nccd.cdc.gov/ddtstrs/).
29 Berger, B, Stenstrom, G, Sundkvist, G. Incidence, prevalence, and mortality of diabetes in a large population. A report from the Skaraborg Diabetes Registry. Diabetes Care 1999; 22: 773–8.
30 Ryan, R, Newnham, A, Khunti, K, Majeed, A. New cases of diabetes mellitus in England and Wales, 1994–1998: database study. Public Health 2005; 119: 892–9.
31 Garancini, MP, Gobbi, C, Errera, A, Sergi, A, Gallus, G. Age-specific incidence and duration of known diabetes. The Cremona Study. Diabetes Care 1996; 19: 1279–82.

Treatment with antipsychotics and the risk of diabetes in clinical practice

  • Lars Vedel Kessing (a1), Anders Frøkjær Thomsen (a1), Ulla Brasch Mogensen (a2) and Per Kragh Andersen (a2)

Metrics

Altmetric attention score

Full text views

Total number of HTML views: 0
Total number of PDF views: 0 *
Loading metrics...

Abstract views

Total abstract views: 0 *
Loading metrics...

* Views captured on Cambridge Core between <date>. This data will be updated every 24 hours.

Usage data cannot currently be displayed

Treatment with antipsychotics and the risk of diabetes in clinical practice

  • Lars Vedel Kessing (a1), Anders Frøkjær Thomsen (a1), Ulla Brasch Mogensen (a2) and Per Kragh Andersen (a2)
Submit a response

eLetters

We encountered an error trying to retrieve eLetters for this article. Please try again or contact Customer Services

×

Reply to: Submit a response


Your details


Conflicting interests

Do you have any conflicting interests? *